Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals Inc (NQ: ABOS )

4.070 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.070
Bid (Size) 4.030 (3)
Ask (Size) 4.070 (92)
Prev. Close 4.070
Today's Range 4.070 - 4.070
52wk Range 3.020 - 10.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
5 Value Stocks In The Healthcare Sector
 
Via Benzinga

Performance

YTD
-22.62%
-22.62%
1 Month
-22.33%
-22.33%
3 Month
-15.38%
-15.38%
6 Month
-57.52%
-57.52%
1 Year
-7.08%
-7.08%

More News

Read More
Earnings Scheduled For March 27, 2023
Via Benzinga
Earnings Preview For Acumen Pharmaceuticals
Via Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Preview: Acumen Pharmaceuticals
Via Benzinga
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
From Acumen Pharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
How Is The Market Feeling About Acumen Pharmaceuticals?
Via Benzinga
RPM International, Lamb Weston And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Bank of America To $36? Plus This Analyst Slashes PT On Citigroup
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.